Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$33.8m for renamed NeuroVista:

This article was originally published in Clinica

Executive Summary

NeuroVista this week confirmed its name change from BioNeuronics and reported completion of a series B financing. The proceeds of the funding totalled $33.8m, which the Seattle, Washington-based epilepsy treatment technology specialist aims to channel into the continuing development of its epilepsy-based devices and clinical research programme. The principal investment was made by Advanced Technology Ventures and Delphi Ventures, while series A investors Three Arch Partners, Sprout Group and Foundation Medical Partners also contributed in the round. Epilepsy's severity is outlined by the Epilepsy Foundation which reports 2.5 million people suffer from epilepsy in the US alone, costing the government an annual $15.5 bn.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048384

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel